Ibrutinib (USAN, also known as PCI-32765 and marketed under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase (BTK).

CAS：936563-96-1
中文别名：
英文别名：2-​Propen-​1-​one, 1-​[(3R)​-​3-​[4-​amino-​3-​(4-​phenoxyphenyl)​-​1H-​pyrazolo[3,​4-​d]​pyrimidin-​1-​yl]​-​1-​piperidinyl]​-;
分子式：C25H24N6O2
分子量：440.497
精确质量：440.196
Psa：99.16
Logp：4.7364

MDL号：MFCD20261150